KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Current Deferred Revenue: 2013-2023

Historic Current Deferred Revenue for Palvella Therapeutics (PVLA) over the last 8 years, with Sep 2023 value amounting to $994,000.

  • Palvella Therapeutics' Current Deferred Revenue fell 94.63% to $994,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $994,000, marking a year-over-year decrease of 94.63%. This contributed to the annual value of $20.8 million for FY2022, which is 17.09% down from last year.
  • As of Q3 2023, Palvella Therapeutics' Current Deferred Revenue stood at $994,000, which was down 94.38% from $17.7 million recorded in Q2 2023.
  • In the past 5 years, Palvella Therapeutics' Current Deferred Revenue ranged from a high of $28.4 million in Q2 2019 and a low of $994,000 during Q3 2023.
  • In the last 3 years, Palvella Therapeutics' Current Deferred Revenue had a median value of $20.9 million in 2022 and averaged $20.3 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 222.75% in 2021, then tumbled by 94.63% in 2023.
  • Quarterly analysis of 5 years shows Palvella Therapeutics' Current Deferred Revenue stood at $11.3 million in 2019, then grew by 12.18% to $12.6 million in 2020, then skyrocketed by 98.91% to $25.1 million in 2021, then decreased by 17.09% to $20.8 million in 2022, then plummeted by 94.63% to $994,000 in 2023.
  • Its Current Deferred Revenue was $994,000 in Q3 2023, compared to $17.7 million in Q2 2023 and $26.7 million in Q1 2023.